Wu Yanmeizhi, Yu Shan, Qiao Hong
Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Pathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Front Pharmacol. 2022 Sep 1;13:990445. doi: 10.3389/fphar.2022.990445. eCollection 2022.
Immune checkpoint inhibitors (ICIs) fight tumor progression by activating immune conditions. The inflammatory factors are playing a functional role in programmed death-1 (PD-1) or other immune checkpoints. They are involved in regulating the expression of programmed death ligand-1 (PD-L1), the only predictor recognized by the guidelines in response to ICIs. In addition, abundant components of the tumor microenvironment (TME) all interact with various immune factors contributing to the response to ICIs, including infiltration of various immune cells, extracellular matrix, and fibroblasts. Notably, the occurrence of immune-related adverse events (irAEs) in patients receiving ICIs is increasingly observed in sundry organs. IrAEs are often regarded as an inflammatory factor-mediated positive feedback loop associated with better response to ICIs. It deserves attention because inflammatory factors were observed to be different when targeting different immune checkpoints or in the presence of different irAEs. In the present review, we address the research progresses on regulating inflammatory factors for an intentional controlling anti-cancer response with immune checkpoint inhibitors.
免疫检查点抑制剂（ICIs）通过激活免疫状态来对抗肿瘤进展。炎症因子在程序性死亡-1（PD-1）或其他免疫检查点中发挥作用。它们参与调节程序性死亡配体-1（PD-L1）的表达，PD-L1是指南认可的唯一可预测ICIs疗效的指标。此外，肿瘤微环境（TME）的多种成分均与各种免疫因子相互作用，这些免疫因子有助于对ICIs产生反应，包括各种免疫细胞的浸润、细胞外基质和成纤维细胞。值得注意的是，接受ICIs治疗的患者在各个器官中出现免疫相关不良事件（irAEs）的情况越来越多。IrAEs通常被视为与对ICIs的更好反应相关的炎症因子介导的正反馈回路。这值得关注，因为在针对不同免疫检查点或存在不同irAEs时，观察到炎症因子有所不同。在本综述中，我们阐述了通过调节炎症因子来有意控制免疫检查点抑制剂抗癌反应的研究进展。
